Emerging genomic technologies and the concept of personalized medicine: An overview of ethical, legal and social implications

Cell Cycle

Volumn 7, Issue 15, 2008, Pages 2278-2285

  Glinskii, Victoria G ^a,b   Glinsky, Gennadi V ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b President's Council on Bioethics   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Genetic Information Nondiscriminatin Act (GINA); Genetic testing; Genomics; Human Genome Project; Microarrays; Personalized medicine

Indexed keywords

DNA FINGERPRINTING; DNA MICROARRAY; ETHICS; GENE TECHNOLOGY; GENETIC DATABASE; GENETIC INFORMATION NONDISCRIMINATION ACT; GENETIC PRIVACY; GENOME ANALYSIS; GENOMICS; GOVERNMENT; HEALTH CARE POLICY; HUMAN; HUMAN GENOME PROJECT; LAW; LEGAL ASPECT; PHARMACOGENETICS; REVIEW; SOCIAL ASPECT; UNITED STATES;

EID: 48849115097     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6476     Document Type: Review

References (17)

1. West M, Ginsburg GS, Andrew T, Huang AT, Nevins JR. Embracing the complexity of genomic data for personalized medicine. Genome Research 2006; 16:559-66.
2. Snyderman R, Langheier J. Prospective health care: the second transformation of medicine. Genome Biology 2006; 7:104.
3. Somatic cell nuclear transfer - how science outpaces law. Nature Biotechnology 2003; 21:969-70.
4. Making the most of microarrays. Nature Biotechnology 2006; 9:1039.
5. Billings PR. Genetic nondiscrimination. Nature Genetics 2005; 37:559-60.
6. Norman-Bloodsaw V. Lawrence Berkeley Laboratory. Fed Report 1997; 135:1260-76.
7. Washington-Business Health Update. National Business Group on Health, Vol. XVI, No. 2 2007.
8. Lavis JN, Ross SE, Hurley JE, Hohenadel JM, Stoddart GL, Woodward CA, Abelson J. Examining the role of health services research in public policymaking. The Milbank Quarterly 2002; 80:125-54.
9. Sorian R, Baugh T. Power of information: closing the gap between research and policy. Health Affairs 2002; 264-73.
10. Javitt GH. Policy implications of genetic testing: Not just for geneticists anymore. Advances in Chronic Kidney Disease 2006; 13:178-82.
11. Glinsky GV. Phenotype-defining functions of multiple non-coding RNA pathways. Cell Cycle 2008; 7:1630-9.
12. Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 2005; 4:1171-5.
13. Glinsky GV, Glinskii AB, Berezovskaya O. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. Journal of Clinical Investigation 2005; 115:1503-21.
14. Glinsky GV. Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem Cells Reviews 2007; 3:79-93.
15. Glinsky GV. "Stemness" genomics law governs clinical behavior of human cancer: Implications for decision making in disease management. Journal of Clinical Oncology 2008; 26:2846-53.
16. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnolog 2006; 24:985-95.
17. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The connectivity map: using gene-expression signatures to connect small molecules, genes and disease. Science 2006; 313:1929-35.